Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Accumulated Expenses (2022 - 2025)

Entrada Therapeutics (TRDA) has 4 years of Accumulated Expenses data on record, last reported at $17.7 million in Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 32.52% year-over-year to $17.7 million; the TTM value through Dec 2025 reached $17.7 million, up 32.52%, while the annual FY2025 figure was $17.7 million, 32.52% up from the prior year.
  • Accumulated Expenses reached $17.7 million in Q4 2025 per TRDA's latest filing, up from $15.5 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $17.7 million in Q4 2025 and bottomed at $4.5 million in Q1 2022.
  • Average Accumulated Expenses over 4 years is $10.5 million, with a median of $11.2 million recorded in 2023.
  • Peak YoY movement for Accumulated Expenses: surged 158.09% in 2023, then decreased 24.7% in 2024.
  • A 4-year view of Accumulated Expenses shows it stood at $7.6 million in 2022, then surged by 49.49% to $11.3 million in 2023, then grew by 17.82% to $13.3 million in 2024, then skyrocketed by 32.52% to $17.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Expenses were $17.7 million in Q4 2025, $15.5 million in Q3 2025, and $11.8 million in Q2 2025.